Molecole per infezioni da Gram positivi (Clinical Breakpoints)
| Elenco di possibili molecole antibiotiche per la valutazione della sensibilità in agenti batterici patogeni Gram positivi isolati nel bovino. | ||||||||||||||||
| Gram +vi$ | CLSI VET 01S-Ed 6 | CLSI M100 S33 | CLSI M45 3rd Ed | CA-SFM VET 2023 | EUCAST ECOFF 2023 | |||||||||||
| S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | ||
| Beta Lattamici | Penicillina Staphylococcus spp (HD) | P | NP | P | P | NP | P | NP | NP | NP | P | NP | P | NP | NP | P |
| Penicillina (Streptococcus beta haemolytic group HD) | P | NP | NP | P | NP | NP | NP | NP | NP | P | NP | P | NP | NP | P | |
| Penicillina (Corineformi) | NP | NP | NP | NP | NP | NP | P | P | P | NP | NP | NP | NP | NP | P | |
| Cefoxitina^ Staphylococcus (HD) | P | NP | P | P | NP | P | NP | NP | NP | NP | NP | NP | NP | NP | P | |
| (Ceftiofur) | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | P | |
| Cefotaxime^ Staphylococcus spp (HD) | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | P | |
| Cefotaxime (Streptococcus beta haemolytic group ) | NP | NP | NP | P | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | |
| Cefotaxime (Corineformi) | NP | NP | NP | NP | NP | NP | P | P | P | NP | NP | NP | NP | NP | NP | |
| Gram +vi$ | CLSI VET 01S-Ed 6 (HD) | CLSI M100 S33 | CLSI M45 3rd Ed | CA-SFM VET 2023 | EUCAST ECOFF 2023 | |||||||||||
| S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | ||
| (Fluoro)chinolonici | Ciprofloxacin Staphylococcus spp (HD) | NP | NP | NP | P | p | P | NP | NP | NP | NP | NP | NP | NP | NP | P |
| Ciprofloxacin (Corineformi) | NP | NP | NP | NP | NP | NP | P | P | P | NP | NP | NP | NP | NP | P | |
| Ciprofloxacin S.agalactie | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | P | |
| Enrofloxacin (Staphylococcus) | NP | NP | NP | NP | NP | NP | NP | NP | NP | P | NP | P | NP | NP | NP | |
| Enrofloxacin (Streptococcus ) | NP | NP | NP | NP | NP | NP | NP | NP | NP | P | NP | P | NP | NP | NP | |
| Gram +vi$ | CLSI VET 01S-Ed 6 (HD) | CLSI M100 S33 | CLSI M45 3rd Ed | CA-SFM VET 2023 | EUCAST ECOFF 2023 | |||||||||||
| S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | ||
| Aminoglicosidi (Aminociclitoli) | Kanamicina Staphylococcus spp (HD) | NP | NP | NP | NP | NP | NP | NP | NP | NP | P | NP | P | NP | NP | P |
| (Kanamicina) Streptococcus spp | NP | NP | NP | NP | NP | NP | NP | NP | NP | P | NP | P | NP | NP | NP | |
| Gentamicina Staphylococcus spp (HD) | P | P | P | P | p | P | NP | NP | NP | P | NP | P | NP | NP | P | |
| Gentamicina (Corineformi) | NP | NP | NP | NP | NP | NP | P | P | P | NP | NP | NP | NP | NP | NP | |
| (Gentamicina) Streptococcus | NP | NP | NP | NP | NP | NP | NP | NP | NP | P | NP | P | NP | NP | NP | |
| (Gentamicina) Streptococcus agalactiae | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | P | |
| Gram +vi$ | CLSI VET 01S-Ed 6 (HD) | CLSI M100 S33 | CLSI M45 3rd Ed | CA-SFM VET 2023 | EUCAST ECOFF 2023 | |||||||||||
| S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | ||
| Macrolidi | Eritromicina (Staphylococcus HD) | P | P | P | P | p | P | NP | NP | NP | P | NP | P | NP | NP | P |
| Eritromicina Streptococcus spp (HD) | P | P | P | NP | NP | NP | NP | NP | NP | P | NP | P | NP | NP | NP | |
| Eritromicina (Streptococcus beta haemolityc group) | NP | NP | NP | P | p | P | NP | NP | NP | NP | NP | NP | NP | NP | P | |
| Eritromicina (Corineformi) | NP | NP | NP | NP | NP | NP | P | P | P | NP | NP | NP | NP | NP | P | |
| Gram +vi$ | CLSI VET 01S-Ed 6 (HD) | CLSI M100 S33 | CLSI M45 3rd Ed | CA-SFM VET 2023 | EUCAST ECOFF 2023 | |||||||||||
| S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | ||
| Lincosamidi | Clindamicina Streptococcus spp (HD) | P | P | P | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP |
| Clindamicina Staphylococcus spp (HD) | NP | NP | NP | P | P | P | NP | NP | NP | NP | NP | NP | NP | NP | P | |
| Clindamicina (Streptococcus beta haemolityc group) | NP | NP | NP | P | P | P | NP | NP | NP | NP | NP | NP | NP | NP | P | |
| Gram +vi$ | CLSI VET 01S-Ed 6 (HD) | CLSI M100 S33 | CLSI M45 3rd Ed | CA-SFM VET 2023 | EUCAST ECOFF 2023 | |||||||||||
| S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | ||
| Rifaximine | Rifampicina Staphylococcus spp (HD) | P | P | P | P | P | P | NP | NP | NP | NP | NP | NP | NP | NP | P |
| Gram +vi$ | CLSI VET 01S-Ed 6 (HD) | CLSI M100 S33 | CLSI M45 3rd Ed | CA-SFM VET 2023 | EUCAST ECOFF 2023 | |||||||||||
| S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | ||
| Amfenicoli | Cloramfenicolo§ Staphylococcus spp (HD) | P | P | P | P | P | P | NP | NP | NP | P | NP | P | NP | NP | P |
| Cloramfenicolo§ Streptococcus spp (HD) | P | P | P | NP | NP | NP | NP | NP | NP | P | NP | P | NP | NP | NP | |
| Cloramfenicolo (Streptococcus beta haemolityc group) | NP | NP | NP | P | P | P | NP | NP | NP | NP | NP | NP | NP | NP | NP | |
| Florfenicol (Staphylococcus spp) | NP | NP | NP | NP | NP | NP | NP | NP | NP | P | NP | P | NP | NP | P | |
| Florfenicol (Streptococcus beta haemolytic group) | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | P | |
| Gram +vi$ | CLSI VET 01S-Ed 6 (HD) | CLSI M100 S33 | CLSI M45 3rd Ed | CA-SFM VET 2023 | EUCAST ECOFF 2023 | |||||||||||
| S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | ||
| Sulfonamidi | Sulfonamidi (Staphylococcus spp) | NP | NP | NP | NP | NP | NP | NP | NP | NP | P | NP | P | NP | NP | NP |
| Gram +vi$ | CLSI VET 01S-Ed 6 (HD) | CLSI M100 S33 | CLSI M45 3rd Ed | CA-SFM VET 2023 | EUCAST ECOFF 2023 | |||||||||||
| S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | ||
| Trimethoprim | Trimethoprim (Staphylococcus) | NP | NP | NP | NP | NP | NP | NP | NP | NP | P | NP | P | NP | NP | P |
| Gram +vi$ | CLSI VET 01S-Ed 6 (HD) | CLSI M100 S33 | CLSI M45 3rd Ed | CA-SFM VET 2023 | EUCAST ECOFF 2023 | |||||||||||
| S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | ||
| Trimethoprim-sulfamethoxazole | Tetraciclina Staphylococcus spp (HD) | P | NP | P | P | NP | P | NP | NP | NP | NP | NP | NP | NP | NP | P |
| Streptococcus spp | NP | NP | NP | NP | NP | NP | NP | NP | NP | P | NP | P | NP | NP | P | |
| Gram +vi$ | CLSI VET 01S-Ed 6 (HD) | CLSI M100 S33 | CLSI M45 3rd Ed | CA-SFM VET 2023 | EUCAST ECOFF 2023 | |||||||||||
| S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | S≤ | I (range) | R≥ | ||
| Tetracicline | Tetraciclina Staphylococcus spp (HD) | P | P | P | P | P | P | NP | NP | NP | P | NP | P | NP | NP | P |
| Tetraciclina Streptococcus spp (HD) | P | P | P | P | P | P | NP | NP | NP | P | NP | P | NP | NP | NP | |
| Tetraciclina (Streptococcus spp beta haemolytic group) | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP | P | |
Note:
- P: Clinical breakpoint/Epidemiological cutoff presente
- NP: Clinical breakpoint/Epidemiological cutoff non presente
- HD: Human-derived (breakpoints derivati dallo Standard Umano, come da documento CLSI VET)
- $ Per Staphyloccus aureus, Streptococcus, altri Gram +vi (Trueperella pyogenes)
- ^ Per Staphylococcus aureus
- Gli antibiotici tra parentesi sono da considerarsi facoltativi